Relapsed or Refractory B-cell Lymphoma
Conditions
Brief summary
This is a dose-escalation, single-arm, single-center open study which aims to evaluate the maximum tolerated dose (MTD) and dose-dependent toxicity (DLT) of a novel oncolytic vaccinia virus expressing bispecific antibody RGV004 in patients with relapsed/refractory B-cell lymphoma,
Detailed description
Oncolytic vaccinia virus administered by intratumoral injection
Interventions
BIOLOGICALRGV004
a genetically-engineered vaccinia virus (encoding CD19/CD3 bispecific antibody)
Sponsors
Hangzhou Rongu Biotechnology Co., Ltd.
Second Affiliated Hospital, School of Medicine, Zhejiang University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Age ≥ 18 years old, the upper limit is 75 years old, there is no restriction on men and women; 2. ECOG score 0-1; 3. Histological diagnosis of non-Hodgkin B-cell lymphoma (NHL) \[diagnostic criteria according to WHO2008\], including diffuse large B-cell lymphoma (DLBCL) non-specific, primary mediastinal large B-cell lymphoma (PMBCL) , Mantle cell lymphoma (MCL), transformed follicles Cell lymphoma (TFL) and other indolent B-cell NHL transformants; 4. CD19 positive (immunohistochemistry or flow cytometry); 5. DLBCL refractory (refractory) or relapse is defined as: complete remission is not achieved after 2-line treatment; disease appears during any treatment Disease progression, or disease stable time equal to or less than 6 months; or disease progression or recurrence within 12 months after autologous hematopoietic stem cell transplantation; 6. MCL: Complete remission has not been achieved after 2-line treatment (including BTK inhibitors); disease progression during any treatment, or disease stable time equal to or less than 6 months; or within 12 months after autologous hematopoietic stem cell transplantation Disease progression or recurrence; 7. There is at least one measurable superficial lesion, and any long diameter of the lymph node lesion is greater than 1.5 cm or any long diameter of the extranodal lesion is greater than 1.0 cm, and the PET-CT scan lesion is ingested (SUV is greater than the liver blood pool); 8. Peripheral blood neutrophil absolute value ≥ 2000/mm3, platelet ≥ 50,000/mm3; 9. Heart, liver and kidney functions: creatinine \<1.5mg/dL; ALT (alanine aminotransferase) / AST (aspartate aminotransferase) below 2.5 times the upper limit of normal; total bilirubin \<1.5mg/dL; cardiac ejection fraction ( EF) ≥50%; 10. Have sufficient understanding and voluntarily sign the informed consent form; 11. Women with fertility must undergo a negative serum pregnancy test and agree to implement effective birth control measures during the treatment phase and within 60 days after the last application of the oncolytic virus; 12. Male patients must agree to implement effective birth control measures during the study period and within 60 days after the last viral treatment.
Exclusion criteria
1. There is a history of other tumors; 2. Inoculate vaccinia vaccine 3 months before the study treatment and during the study treatment period; 3. Have received gene therapy or any type of oncolytic virus therapy within 3 months before the study treatment; 4. Other open wounds; 5. Active autoimmune diseases; 6. Active infection that cannot be controlled; 7. HIV infection, uncontrolled HBV, HCV, and syphilis infection; 8. Known lymphoma of the central nervous system; 9. Clinically important heart disease; 10. Allergic to albumin or egg products; 11. Have undergone similar operations such as organ transplantation; 12. Systemic treatment of skin diseases is required; 13. A history of severe systemic reactions or side effects after vaccinia vaccine injection; 14. Known dependence on alcohol or viruses; 15. Pregnant or lactating female patients
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To define the Max tolerated dose (MTD) of RGV004 | Up to 28 days | According to the principle of '3+3' dose escalation, if one patient experiences a Dose limiting Toxicity (DLT), up to three additional patients will be treated at the same dose level. If DLT is observed in only one of six patients treated at a given dose level, the next cohort of three patients will be treated at the next higher dose level. If two or more patients experience DLT at a particular dose level, then the dose escalation will cease and any subsequent patients will be treated at a lower dose level. Thus finding the Max tolerated dose (MTD) |
| Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 | Up to 2 years | To evaluate the number of Grade III and above side effects assessed by CTCAE v5.0 for patients who received intratumoral administration of RGV004 injection in patients with R/R B-cell lymphoma. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Objective remission rate (ORR) | Up to 2 years | The percentage of participants who achieved complete remission (CR) and partial remission (PR) over all participants |
| RGV004 viral DNA in blood | Up to 2 years | Viral DNA load will be summarized by cohort |
| RGV004 viral shedding in saliva | Up to 2 years | Viral DNA will be analyzed by qPCR |
| RGV004 viral shedding in urine | Up to 2 years | Viral DNA will be analyzed by qPCR |
Countries
China
Contacts
Primary ContactWenbin Qian
Outcome results
None listed